Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Friday announced a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Olumiant (baricitinib) for the treatment of adolescents with severe alopecia areata (AA), a chronic immune disease that causes hair loss.
Olumiant is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly.
This positive opinion marks the next step toward European regulatory approval of Olumiant for adolescents aged 12 to under 18 with severe AA, and it is now referred to the European Commission for final action. A decision from the European Commission is expected in the next one to two months.
According to the company, the positive CHMP opinion is supported by 36-week data from the Phase 3 BRAVE-AA-PEDS study evaluating the safety and efficacy of once-daily, oral Olumiant compared with placebo in the cohort of patients ages 12 to under 18. Treatment with Olumiant helped many adolescents achieve near-complete scalp hair regrowth. Additionally, many patients achieved successful eyebrow and eyelash regrowth.
Lilly has also submitted Olumiant in the United States for approval to treat severe AA in adolescents, with a decision expected in the second half of 2026.
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia